Sei Investments Co. Boosts Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Sei Investments Co. raised its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 61.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 85,279 shares of the company’s stock after purchasing an additional 32,423 shares during the period. Sei Investments Co. owned 0.08% of Amylyx Pharmaceuticals worth $1,185,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Landscape Capital Management L.L.C. lifted its position in shares of Amylyx Pharmaceuticals by 17.5% during the 4th quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after buying an additional 1,825 shares during the last quarter. KBC Group NV purchased a new stake in Amylyx Pharmaceuticals in the 1st quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Amylyx Pharmaceuticals by 54.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after acquiring an additional 1,890 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Amylyx Pharmaceuticals in the 4th quarter worth about $25,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Amylyx Pharmaceuticals by 14.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company’s stock valued at $216,000 after acquiring an additional 2,265 shares during the period. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Stock Up 4.2%

Shares of NASDAQ AMLX opened at $23.63 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 52 week low of $7.63 and a 52 week high of $24.60. The business has a 50-day simple moving average of $17.74 and a two-hundred day simple moving average of $15.86. The company has a market cap of $2.63 billion, a P/E ratio of -16.52 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Equities research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.42 EPS for the current year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the sale, the insider directly owned 194,090 shares in the company, valued at $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on AMLX shares. Mizuho increased their target price on shares of Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a research report on Monday, July 20th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Citigroup upped their price target on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Finally, Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.38.

Key Stories Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Amylyx was identified by Zacks as one of four biotech companies with major second-half 2026 catalysts. The potential catalysts include regulatory decisions and late-stage clinical-trial readouts, which could provide important updates on the company’s pipeline and support investor optimism. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $34 price target for Amylyx. The target implies further upside from recent trading levels and may have helped reinforce the bullish view among investors. Amylyx Pharmaceuticals Analyst Coverage
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior reporting period, with a zero-day days-to-cover ratio. Because the figures appear anomalous, they provide little meaningful information about short-selling pressure or potential short-covering demand.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across the 2026–2028 period, including estimates of losses of $1.49 per share for fiscal 2026, $1.40 for fiscal 2027, and $1.08 for fiscal 2028. Quarterly loss estimates were also lowered to $0.35 per share for the third quarter of 2026 and $0.37 for the fourth quarter, signaling expectations for continued cash burn and weaker profitability than previously projected. HC Wainwright Amylyx Estimates

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.